ReviewRSC advances2025
Tellurium nanoparticles as antimicrobial agents for multi-drug-resistant infections.
Review in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Green-synthesized tellurium nanoparticles as a multifunctional leather finishing agent: antimicrobial and mechanical enhancement.Scientific reports · 2026Article
- Metalloids: Semi as Metals yet Full of Antimicrobial Potential.ChemMedChem · 2026Review
- Effect of CuO on the Structural, Antimicrobial, and Redox Activity of TiOGels (Basel, Switzerland) · 2026Article
- Unveiling the potential of inorganic nanoparticle-based scaffolds in wound healing: advances in antimicrobial and regenerative strategies.Nanoscale advances · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rise of multi-drug-resistant (MDR) infections has driven interest in alternative antimicrobial agents, with tellurium nanoparticles (TeNPs) emerging as a promising solution. TeNPs possess unique physicochemical properties, including controlled size, shape, and surface chemistry, which contribute to their potent antimicrobial activity. Their mechanisms of action include reactive oxygen species (ROS) generation, membrane disruption, inhibition of essential microbial proteins and enzymes, and direct damage to DNA and RNA. These multifaceted interactions enable TeNPs to combat a broad spectrum of bacterial and fungal pathogens effectively. In addition to their direct antimicrobial effects, TeNPs have demonstrated efficacy in disrupting and preventing biofilm formation, a key factor in persistent infections. Their application in treating infected wounds has shown promise by reducing microbial burden while promoting wound healing. Notably, TeNPs exhibit synergistic effects when combined with conventional antibiotics, enhancing bacterial eradication and potentially mitigating resistance development. However, concerns remain regarding their cytotoxicity, biodegradability, and long-term clearance in mammalian systems. Addressing these issues through surface modifications and controlled release strategies is essential for safe biomedical applications. Despite their potential, challenges such as scalable production, stability, and regulatory approval hinder widespread use. Future research will focus on advanced functionalization to enhance selectivity, emerging applications such as biofilm disruption and antiviral therapies, and integration with smart technologies for infection monitoring. A structured roadmap for clinical translation is necessary to move TeNP-based therapies from experimental studies to medical practice. The continued development of TeNPs could revolutionize antimicrobial strategies and address the global antibiotic resistance crisis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.